UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                                 Date of Report:

                                  March 6, 2008

                          MEDISCIENCE TECHNOLOGY CORP.
                          ----------------------------

               (Exact Name of Registrant as Specified in Charter)
            New Jersey             0-7405              22-1937826
            ----------             ------              ----------
            (State of          (Commission           (IRS Employer
           Incorporation)       File Number)        Identification No.)

                               1235 Folkstone Way
                          Cherry Hill, New Jersey 08034
                              --------------------
               (Address of principal executive offices) (Zip Code)

                                 (215) 485-0362
                                 --------------
                         (Registrant's telephone number)

         Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2 below):

         [_] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)

         [_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)

         [_] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))

         [_] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))

<PAGE>


Item 1.01. Entry into a Material Definitive Agreement.

The Registrant, Mediscience Technology Corp. ("Mediscience"), executed an
agreement dated as of March 3, 2008 (the "Agreement") with Infotonics Technology
Center Inc., a New York not-for-profit corporation, under which Infotonics
Technology Center Inc. ("ITC") agrees to develop through advances in optical,
mechanical, electrical, software and diagnostic aspects, and to commercialize,
Mediscience's medical diagnostic systems using tissue autofluorescence to detect
disease states. The companies have agreed that OTC will issue a series of
purchase orders covering a three month period and detailing the work to be
performed by ITC. Mediscience will pay for the work to be performed by ITC
through monthly invoices submitted to Mediscience. The Agreement is also
intended to benefit BioScopix, Inc., Mediscience's wholly-owned subsidiary that
is expected to own the medical diagnostic systems using tissue autofluorescence
to detect disease states as that technology is further developed.

The terms of the Agreement described above are only a summary of the Agreement
and are qualified in their entirety by reference to the Agreement which is
attached hereto as Exhibits 10.1 and incorporated by reference into this Current
Report on Form 8-K.

Item 9.01.  Financial Statements and Exhibits.

(d) Exhibits.

10.1  Agreement dated as of March 3, 2008 between Mediscience and Infotonics
      Technology Center Inc.


<PAGE>



                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                           MEDISCIENCE TECHNOLOGY CORPORATION


Date: March 12, 2008                       By:   /s/Peter Katevatis
                                                 -----------------------
                                                 Peter Katevatis
                                                 Chief Executive Officer